IN2014DN03224A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN03224A IN2014DN03224A IN3224DEN2014A IN2014DN03224A IN 2014DN03224 A IN2014DN03224 A IN 2014DN03224A IN 3224DEN2014 A IN3224DEN2014 A IN 3224DEN2014A IN 2014DN03224 A IN2014DN03224 A IN 2014DN03224A
- Authority
- IN
- India
- Prior art keywords
- protein
- bioactive molecules
- peptide
- penetrating
- functional groups
- Prior art date
Links
- 230000000975 bioactive effect Effects 0.000 abstract 3
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- 210000004962 mammalian cell Anatomy 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 230000000149 penetrating effect Effects 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101100239628 Danio rerio myca gene Proteins 0.000 abstract 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 abstract 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 101150111214 lin-28 gene Proteins 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/34—Belt retractors, e.g. reels
- B60R22/341—Belt retractors, e.g. reels comprising energy-absorbing means
- B60R22/3413—Belt retractors, e.g. reels comprising energy-absorbing means operating between belt reel and retractor frame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
- B60R2022/286—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices using deformation of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
- B60R2022/289—Energy-absorption curves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mechanical Engineering (AREA)
- Toxicology (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550213P | 2011-10-21 | 2011-10-21 | |
PCT/US2012/061391 WO2013059831A1 (fr) | 2011-10-21 | 2012-10-22 | Nanoparticules fonctionnalisées pour l'administration intracellulaire de molécules biologiquement actives |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN03224A true IN2014DN03224A (fr) | 2015-05-22 |
Family
ID=48141479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3224DEN2014 IN2014DN03224A (fr) | 2011-10-21 | 2012-10-22 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9675708B2 (fr) |
EP (2) | EP2769217A4 (fr) |
JP (3) | JP2014532628A (fr) |
KR (3) | KR20200040924A (fr) |
CN (2) | CN104094119A (fr) |
AU (3) | AU2012325723A1 (fr) |
BR (1) | BR112014009753B1 (fr) |
CA (2) | CA2853128C (fr) |
HK (1) | HK1201089A1 (fr) |
IN (1) | IN2014DN03224A (fr) |
MX (3) | MX367656B (fr) |
RU (2) | RU2018135567A (fr) |
SG (2) | SG10201601746TA (fr) |
WO (1) | WO2013059831A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX367656B (es) * | 2011-10-21 | 2019-08-29 | Stemgenics Inc | Nanopartículas funcionalizadas para suministro intracelular de moléculas biológicamente activas. |
ES2750258T3 (es) * | 2013-03-01 | 2020-03-25 | Stealth Biotherapeutics Corp | Métodos y composiciones para la prevención o tratamiento del síndrome de Barth |
CN116474071A (zh) | 2013-03-01 | 2023-07-25 | 康德生物医疗有限公司 | 治疗线粒体疾病的方法 |
WO2014209905A2 (fr) | 2013-06-26 | 2014-12-31 | Stealth Peptides International, Inc. | Méthodes et compositions destinées à détecter et à diagnostiquer des maladies et des affections |
US11306326B2 (en) | 2013-08-23 | 2022-04-19 | Rutgers, The State University Of New Jersey | Biologically active synthetic nanoparticle constructs and methods of use thereof |
WO2015027243A2 (fr) | 2013-08-23 | 2015-02-26 | Rutgers The State University Of New Jersey | Constructions nanoparticulaires synthétiques biologiquement actives et leurs méthodes d'utilisation |
EP3105318A1 (fr) * | 2014-02-10 | 2016-12-21 | Nvigen, Inc. | Nanocomposition de modulation cellulaire, et procédés d'utilisation |
CN105440112A (zh) * | 2015-12-07 | 2016-03-30 | 国家纳米科学中心 | 多肽-白蛋白偶联药物、其制备方法及应用 |
WO2017210638A1 (fr) * | 2016-06-03 | 2017-12-07 | Stemgenics, Inc. | Reprogrammation directe d'une cellule somatique humaine en cellule différenciée (prédéterminée) sélectionnée avec des nanoparticules fonctionnalisées |
EP3463316A4 (fr) * | 2016-06-03 | 2020-05-27 | Stemgenics, Inc. | Nanoparticules fonctionnalisées pour l'administration intracellulaire de molécules biologiquement actives et leurs procédés de fabrication et d'utilisation |
JP2019534890A (ja) * | 2016-10-11 | 2019-12-05 | ステムジェニクス, インコーポレイテッド | 遺伝子編集ツールによって機能化されたナノ粒子および関連する方法 |
US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
US11701433B2 (en) | 2017-06-05 | 2023-07-18 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
CN108287235B (zh) * | 2018-02-07 | 2021-03-09 | 常州天地人和生物科技有限公司 | 一种高效、稳定的磁性免疫微球的制备和应用 |
US20200326325A1 (en) | 2019-04-12 | 2020-10-15 | Lisa Diamond | Nanosensor chip with compound nanopores |
CN110642876A (zh) * | 2019-10-10 | 2020-01-03 | 南京市口腔医院 | 半胱氨酸修饰金纳米颗粒和制备方法、应用及促进骨组织再生产品 |
CN112472685B (zh) * | 2020-12-10 | 2023-03-24 | 哈尔滨工业大学 | 一种杂化中性粒细胞机器人的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001019405A2 (fr) * | 1999-09-14 | 2001-03-22 | Biomedical Apherese Systeme Gmbh | Nanoparticules magnetiques a effet biochimique, leur procede de production et leur utilisation |
US7329638B2 (en) * | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
CN101389314A (zh) * | 2005-03-14 | 2009-03-18 | 得克萨斯大学体系董事会 | 生物活性fus1肽和纳米颗粒-多肽复合物 |
US8338366B2 (en) * | 2005-03-14 | 2012-12-25 | The Board of Regents of the University of the Texas System | Bioactive FUS1 peptides and nanoparticle-polypeptide complexes |
EP1904932A4 (fr) * | 2005-06-17 | 2013-02-27 | Univ North Carolina | Procedes, systemes et materiaux de fabrication de nanoparticules |
EP2099496A2 (fr) * | 2006-12-08 | 2009-09-16 | Massachusetts Institute of Technology | Administration de nanoparticules et/ou d'agents à des cellules |
CA2672998C (fr) | 2007-01-02 | 2013-08-06 | University Of Central Florida Research Foundation, Inc. | Procedes et materiaux pour la stimulation de la proliferation de cellules souches |
KR100925689B1 (ko) * | 2007-07-25 | 2009-11-10 | 한국생명공학연구원 | 항체와 나노입자를 세포 내로 동시에 전달할 수 있는다기능성 단백질 |
US8283344B2 (en) | 2007-09-10 | 2012-10-09 | Merck & Co., Inc. | Method of treating inherited severe neutropenia |
KR100951719B1 (ko) * | 2007-10-02 | 2010-04-07 | 재단법인서울대학교산학협력재단 | 세포투과성 펩타이드와 형광표지 자성나노입자의 복합체 및그 용도 |
WO2009067756A1 (fr) * | 2007-11-30 | 2009-06-04 | Cytomatrix Pty Ltd | Méthodes d'induction de la pluripotence impliquant la protéine sox2 |
CA2713872A1 (fr) | 2008-02-21 | 2009-08-27 | Burnham Institute For Medical Research | Procedes et compositions lies aux peptides et aux proteines avec des elements c-terminaux |
EP2379577A4 (fr) * | 2008-12-23 | 2012-08-29 | Vivoscript Inc | Compositions et procédés de reprogrammation cellulaire sans modification génétique |
AU2010234539B2 (en) * | 2009-04-07 | 2015-04-09 | Corteva Agriscience Llc | Nanoparticle mediated delivery of sequence specific nucleases |
MX367656B (es) * | 2011-10-21 | 2019-08-29 | Stemgenics Inc | Nanopartículas funcionalizadas para suministro intracelular de moléculas biológicamente activas. |
-
2012
- 2012-10-22 MX MX2018002306A patent/MX367656B/es unknown
- 2012-10-22 JP JP2014537369A patent/JP2014532628A/ja not_active Withdrawn
- 2012-10-22 KR KR1020207010401A patent/KR20200040924A/ko not_active Application Discontinuation
- 2012-10-22 CA CA2853128A patent/CA2853128C/fr active Active
- 2012-10-22 RU RU2018135567A patent/RU2018135567A/ru not_active Application Discontinuation
- 2012-10-22 EP EP12842115.3A patent/EP2769217A4/fr not_active Withdrawn
- 2012-10-22 SG SG10201601746TA patent/SG10201601746TA/en unknown
- 2012-10-22 KR KR20147010620A patent/KR20150001711A/ko active Application Filing
- 2012-10-22 EP EP18160010.7A patent/EP3400956A1/fr not_active Withdrawn
- 2012-10-22 SG SG11201401658SA patent/SG11201401658SA/en unknown
- 2012-10-22 BR BR112014009753-4A patent/BR112014009753B1/pt active IP Right Grant
- 2012-10-22 AU AU2012325723A patent/AU2012325723A1/en not_active Abandoned
- 2012-10-22 CN CN201280063870.2A patent/CN104094119A/zh active Pending
- 2012-10-22 WO PCT/US2012/061391 patent/WO2013059831A1/fr active Application Filing
- 2012-10-22 CN CN201610644097.9A patent/CN106822868A/zh active Pending
- 2012-10-22 CA CA2938661A patent/CA2938661A1/fr not_active Abandoned
- 2012-10-22 RU RU2014120465/15A patent/RU2014120465A/ru unknown
- 2012-10-22 IN IN3224DEN2014 patent/IN2014DN03224A/en unknown
- 2012-10-22 KR KR1020197018256A patent/KR20190077124A/ko not_active Application Discontinuation
- 2012-10-22 MX MX2014004778A patent/MX2014004778A/es unknown
- 2012-10-22 US US14/353,280 patent/US9675708B2/en active Active - Reinstated
-
2014
- 2014-04-21 MX MX2018010696A patent/MX2018010696A/es unknown
-
2015
- 2015-02-12 HK HK15101563.8A patent/HK1201089A1/xx unknown
-
2017
- 2017-06-30 JP JP2017128822A patent/JP6560302B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-31 AU AU2018203848A patent/AU2018203848A1/en not_active Abandoned
- 2018-09-03 JP JP2018164676A patent/JP2018184485A/ja active Pending
-
2020
- 2020-08-27 AU AU2020223737A patent/AU2020223737A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9675708B2 (en) | 2017-06-13 |
AU2020223737A1 (en) | 2020-09-17 |
KR20200040924A (ko) | 2020-04-20 |
AU2012325723A1 (en) | 2014-05-15 |
JP2018184485A (ja) | 2018-11-22 |
SG11201401658SA (en) | 2014-07-30 |
BR112014009753B1 (pt) | 2020-09-15 |
EP2769217A1 (fr) | 2014-08-27 |
MX2014004778A (es) | 2014-10-17 |
KR20150001711A (ko) | 2015-01-06 |
CA2853128C (fr) | 2016-09-27 |
US20140342004A1 (en) | 2014-11-20 |
EP3400956A1 (fr) | 2018-11-14 |
EP2769217A4 (fr) | 2015-06-03 |
WO2013059831A1 (fr) | 2013-04-25 |
BR112014009753A2 (pt) | 2017-04-25 |
MX2018010696A (es) | 2020-09-02 |
AU2018203848A1 (en) | 2018-06-21 |
CN106822868A (zh) | 2017-06-13 |
JP2017165781A (ja) | 2017-09-21 |
CN104094119A (zh) | 2014-10-08 |
HK1201089A1 (en) | 2015-08-21 |
JP6560302B2 (ja) | 2019-08-14 |
SG10201601746TA (en) | 2016-04-28 |
RU2018135567A (ru) | 2018-11-15 |
RU2014120465A (ru) | 2015-11-27 |
KR20190077124A (ko) | 2019-07-02 |
CA2853128A1 (fr) | 2013-04-25 |
MX367656B (es) | 2019-08-29 |
JP2014532628A (ja) | 2014-12-08 |
CA2938661A1 (fr) | 2013-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN03224A (fr) | ||
JP2014532628A5 (fr) | ||
Zhao et al. | A multifunctional, self-healing, self-adhesive, and conductive sodium alginate/poly (vinyl alcohol) composite hydrogel as a flexible strain sensor | |
Shin et al. | Three-dimensional electroconductive hyaluronic acid hydrogels incorporated with carbon nanotubes and polypyrrole by catechol-mediated dispersion enhance neurogenesis of human neural stem cells | |
Park et al. | Graphene oxide flakes as a cellular adhesive: prevention of reactive oxygen species mediated death of implanted cells for cardiac repair | |
Narayanan et al. | Electrospun poly (vinyl alcohol)/reduced graphene oxide nanofibrous scaffolds for skin tissue engineering | |
HRP20150194T1 (hr) | Upotreba rna za reprogramiranje somatskih stanica | |
WO2012058673A3 (fr) | Traitement et surveillance améliorés du cancer au moyen de vecteurs recombinants | |
Rabiee et al. | Green porous benzamide-like nanomembranes for hazardous cations detection, separation, and concentration adjustment | |
MX344219B (es) | Productos farmaceuticos peptidicos mejorados para resistencia a insulina. | |
EP2804586A4 (fr) | Biomatériaux comprenant des peptides se liant à l'acide hyaluronique et des molécules biopolymères bifonctionnelles pour des applications de rétention d'acide hyaluronique et d'ingénierie tissulaire | |
Sy et al. | Morphological diversity, protein adsorption, and cellular uptake of polydopamine-coated gold nanoparticles | |
JP2014513983A5 (fr) | ||
Chen et al. | Biofabrication of nerve fibers with mimetic myelin sheath-like structure and aligned fibrous niche | |
WO2012118988A8 (fr) | Reprogrammation directe de fibroblastes humains en neurones fonctionnels dans des conditions définies | |
GB0916337D0 (en) | Branched addition polymers for use in membranes | |
EP3808378A8 (fr) | Protéines thérapeutiques présentant une demi-vie accrue et leurs procédés de préparation | |
WO2010144698A3 (fr) | Procédés, systèmes et compositions pour la différentiation neuronale de cellules stromales pluripotentes | |
BR112015015123A2 (pt) | composição cosmética, método para aprimoramento da característica de pele e uso de uma composição | |
BR112012021229A2 (pt) | reciclagem de partículas de polímero superabsorvente. | |
EP2460766A4 (fr) | Particule composite, composition pour former une membrane de revêtement, encre d'impression, composition de matiere de revêtement, article revêtu, et film de resine a membrane de revêtement fixee | |
WO2013014677A8 (fr) | Compositions matricielles pour la libération contrôlée de molécules peptidiques et polypeptidiques | |
Tran et al. | Adhesive and self-healing soft gel based on metal-coordinated imidazole-containing polyaspartamide | |
Shin et al. | Novel self-assembly-induced 3D plotting for macro/nano-porous collagen scaffolds comprised of nanofibrous collagen filaments | |
WO2012150098A3 (fr) | Composition pour fibres de kératine |